Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy

Am J Hematol. 2011 Jul;86(7):531-2. doi: 10.1002/ajh.22084. Epub 2011 Jun 14.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adult
  • Aged
  • Benzamides
  • Blood Glucose / metabolism
  • Cohort Studies
  • Constriction, Pathologic / blood
  • Constriction, Pathologic / chemically induced
  • Constriction, Pathologic / surgery
  • Coronary Artery Disease / chemically induced
  • Coronary Artery Disease / therapy
  • Drug Resistance, Neoplasm / drug effects
  • Fasting / blood
  • Female
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Middle Aged
  • Peripheral Arterial Disease / blood
  • Peripheral Arterial Disease / chemically induced*
  • Peripheral Arterial Disease / surgery
  • Piperazines / administration & dosage*
  • Piperazines / adverse effects
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / administration & dosage*
  • Pyrimidines / adverse effects*

Substances

  • Benzamides
  • Blood Glucose
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • nilotinib